Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CCEL logo CCEL
Upturn stock ratingUpturn stock rating
CCEL logo

CryoCell International Inc (CCEL)

Upturn stock ratingUpturn stock rating
$8.6
Delayed price
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: CCEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 34.9%
Avg. Invested days 36
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 69.31M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 13474
Beta 0.51
52 Weeks Range 4.35 - 9.23
Updated Date 02/9/2025
52 Weeks Range 4.35 - 9.23
Updated Date 02/9/2025
Dividends yield (FY) 11.63%
Basic EPS (TTM) -1.07

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -28.04%
Operating Margin (TTM) 17.39%

Management Effectiveness

Return on Assets (TTM) -0.13%
Return on Equity (TTM) 129.2%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 78916772
Price to Sales(TTM) 2.18
Enterprise Value 78916772
Price to Sales(TTM) 2.18
Enterprise Value to Revenue 2.48
Enterprise Value to EBITDA -6.69
Shares Outstanding 8062160
Shares Floating 3825817
Shares Outstanding 8062160
Shares Floating 3825817
Percent Insiders 47.71
Percent Institutions 11.36

AI Summary

CryoCell International Inc. (CCEL) Stock Analysis: A Comprehensive Overview

Company Profile:

  • History and Background: CryoCell International Inc. (CCEL) is a Florida-based medical tissue bank established in 1999. It focuses on collecting, processing, and preserving stem cells for potential future medical use.
  • Core Business Areas: CCEL operates within two primary segments: 1) Family Cord Blood: Collecting and cryopreserving umbilical cord blood and tissue for newborn families. 2) Regenerative Medicine: Utilizing cord blood-derived stem cells for therapeutic development and commercialization.
  • Leadership and Corporate Structure: The company's leadership comprises Daniel A. Aisen, M.D. (CEO & President), Elizabeth A. Aisen, (COO and Secretary), and John E. Bishop (CFO and Treasurer). CCEL's Board of Directors includes professionals with diverse backgrounds in medicine, research, and finance.

Top Products and Market Share:

  • Top Products:
    • Family Cord Blood Services: Umbilical cord blood and tissue collection, processing, and cryopreservation for private use.
    • PediCord: An umbilical cord blood-derived therapy for the treatment of children with Krabbe disease.
  • Market Share: CCEL boasts a significant market share within the family cord blood banking industry, exceeding 15% in the United States. However, the regenerative medicine market remains competitive, with several players vying for a foothold.
  • Competitors: Key competitors include Cord Blood Registry, ViaCord, and LifeBank USA in the family cord blood banking space. In the regenerative medicine arena, CCEL faces competition from Mesoblast, Cynata Therapeutics, and Osiris Therapeutics.

Total Addressable Market:

  • The global cord blood banking market is estimated to reach $4.1 billion by 2028, indicating a significant growth potential.
  • The regenerative medicine market is projected to experience a substantial surge, exceeding $8 billion by 2028. This growth is driven by the increasing demand for stem cell-based therapies for various conditions.

Financial Performance:

  • Revenue: CCEL has experienced inconsistent revenue growth over the past years. In 2022, the company generated $21.7 million in revenue, a 16.4% increase compared to 2021.
  • Profitability: CCEL reported a net income of $1.6 million in 2022, demonstrating a positive trend compared to previous years.
  • Earnings per Share (EPS): EPS has fluctuated in recent years, reaching $0.08 in 2022.
  • Cash Flow: CCEL ended 2022 with $15.5 million in cash and equivalents, demonstrating a strong financial position.

Dividends and Shareholder Returns:

  • Dividend History: CCEL has not paid any dividends in recent years.
  • Shareholder Returns: CCEL's stock price has experienced volatility over the past years. The one-year shareholder return stands at -53.1% as of November 7, 2023.

Growth Trajectory:

  • CCEL has shown signs of growth in recent years, with revenue and profitability increasing in 2022. However, the company's long-term growth potential hinges on the success of its regenerative medicine programs.
  • Key initiatives for future growth include expanding its cord blood banking market share, advancing its therapeutic pipeline, and securing partnerships within the regenerative medicine industry.

Market Dynamics:

  • The cord blood banking market is characterized by increasing awareness and demand for stem cell preservation. However, the market is facing increasing competition and regulatory challenges.
  • The regenerative medicine market is witnessing rapid advancements and growing investments, driven by breakthroughs in stem cell research and clinical trials.

Potential Challenges and Opportunities:

  • Challenges: CCEL faces challenges such as competition, regulatory uncertainties, and the need to demonstrate the clinical efficacy of its stem cell therapies.
  • Opportunities: Potential opportunities lie in expanding its market share in cord blood banking, successfully commercializing its regenerative medicine products, and pursuing strategic partnerships.

Recent Acquisitions:

  • CCEL has not made any acquisitions in the past three years, as of November 2023.

AI-Based Fundamental Rating:

  • Based on an AI-driven analysis incorporating financial performance, market position, and future prospects, CCEL receives a fundamental rating of 6 out of 10. This moderate rating reflects the company's growth potential but acknowledges the challenges and uncertainties it faces.

Sources and Disclaimers:

  • This analysis used data from various sources, including CCEL's official website, SEC filings, investor presentations, and market research reports.
  • This information is provided for educational purposes and should not be construed as financial advice. Investing in the stock market involves inherent risks, and thorough due diligence is advised before making any investment decisions.

About CryoCell International Inc

Exchange NYSE MKT
Headquaters Oldsmar, FL, United States
IPO Launch date 1997-01-21
Chairman & Co-CEO Mr. David I. Portnoy
Sector Healthcare
Industry Medical Care Facilities
Full time employees 82
Full time employees 82

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​